Companies Investors People

Drop to look up

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

Contact
Request a Demo
Request Data Updates
Add a Company

Research

Companies
Investors
People

aVenture

Download App
Pricing
Alternatives

For iPhone and iPad

Resources

Documentation
Use Cases
CLI
MCP
Sitemap

aVenture is an AI-native agentic deep research tool for researching and finding companies and people, and is a high-quality alternative to AlphaSense, CB Insights, Crunchbase, Dealroom, Harmonic, Owler, Perplexity Finance, PitchBook, Preqin, PrivCo, Synaptic, and Tracxn.

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Terms of service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Library

F2G

F2G Website, Blog & Press Pages - aVenture Research

Library

f2g.comCrawled Nov 6, 2026

Topics

Publication type

Search the library

Content origin

Row density

Product

3 pages

A Scientific Breakthrough in Antifungal Treatments/science
F2G’s pipeline includes transformative treatments for deadly fungal infections.
Access to Investigational Therapies for Patients in the United States/early-access-to-investigational-therapies
F2G is developing medicines for serious fungal diseases, including cases where other therapies have failed.
We’re Fighting the Fungal Infection Crisis/fungal-landscape
F2G develops novel antifungals to provide additional treatment options for life-threatening fungal infections.

Press

6 pages

F2G Announces Data from Phase 2b Study at ID Week 2022 Showing Positive Therapeutic Response in Patients with Invasive Fungal Infections Treated with Olorofim/press-release/f2g-announces-data-from-phase-2b-study-at-id-week-2022-showing-positive-therapeutic-response-in-patients-with-invasive-fungal-infections-treated-with-olorofim
The data reflect analysis of the first 100 patients in an ongoing Phase 2b study for invasive fungal infections with limited treatment options.
F2G Announces FDA Filing Acceptance of New Drug Application for Olorofim for the Treatment of Invasive Fungal Infections/press-release/f2g-announces-fda-filing-acceptance-of-new-drug-application-for-olorofim-for-the-treatment-of-invasive-fungal-infections
F2G submitted a new drug application under priority review, with a target action date of June 17, 2023, based on Phase 2 data.
F2G to Present at Biotech Showcase 2023/press-release/f2g-to-present-at-biotech-showcase-2023
F2G to Present Interim Results from Phase 2B Open Label Study of Olorofim in Invasive Fungal Infections at IDWeek 2022/press-release/f2g-to-present-interim-results-from-phase-2b-open-label-study-of-olorofim-in-invasive-fungal-infections-at-idweek-2022

Careers & Hiring

2 pages

Join the fight against fungal infections/careers
F2G seeks employees to contribute to its mission of developing antifungal treatments.
We’re Driving Innovation in Antifungal Therapeutics/culture
F2G’s team consists of experts focused on changing treatment approaches for rare fungal infections.

Team

6 pages

Joe Anderson, PhD/team/joe-anderson-phd
Dr. Joe Anderson is a partner at Sofinnova Partners with over 30 years of experience in health care and life science investments. He previously led investments at Abingworth LLP and cofounded Arix Biosciences plc.
Kaasim Mahmood, MD/team/kaasim-mahmood-md
Dr. Kaasim Mahmood is a General Partner at Advent Life Sciences with over 10 years of experience in life science investments and entrepreneurship. He previously worked in corporate finance at Cutfield Freeman & Co and joined Advent’s investment team after.
Max Klement, PhD/team/max-klement-phd
Dr. Max Klement is a Principal at Novo Ventures with over 10 years of experience in biotechnology and life science venture investments. He previously worked at BioGeneration Ventures and Hummingbird Bioscience.
Nanna Lüneborg, PhD/team/nanna-luneborg-phd
Dr. Nanna Lüneborg is a General Partner at Forbion, focusing on late-stage investments. She serves on the board of BioInvent (BINV) and has previously served on boards of other life science companies.

About

1 page

Corporate Governance/corporate-governance

Contact

1 page

Contact Us and Discover the Future of Antifungal Treatments/contact

Homepage

1 page

Homepage/
F2G focuses on novel antifungals to improve outcomes for patients with rare, invasive fungal infections.

Privacy

3 pages

Cookie Policy/cookie-policy
Privacy Notice for Potential Candidates/privacy-notice
Privacy Policy/privacy-policy